Ocular Therapeutix, Inc. (NASDAQ:OCUL) receives a consensus recommendation of “Moderate Buy” from analysts

Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL – Get Your Free Report ) has received an average recommendation of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $15.67.

Several equities research analysts recently issued reports on the stock. Robert W. Baird lowered their price objective on shares of Ocular Therapeutix from $18.00 to $17.00 and set an “outperform” rating for the company in a research note on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Ocular Therapeutix in a research note on Thursday, August 1st. Piper Sandler reiterated an “overweight” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Friday, June 21st. Finally, TD Cowen downgraded shares of Ocular Therapeutix from a “strong-buy” rating to a “hold” rating in a report on Friday, June 21st.

Get the latest report on OCUL

Ocular Therapeutix stock up 3.2%

Shares of OCUL stock opened at $8.71 on Friday. The company has a current ratio of 16.64, a quick ratio of 16.55, and a debt-to-equity ratio of 0.18. Ocular Therapeutix has a 1 year low of $2.00 and a 1 year high of $11.31. The company has a fifty day simple moving average of $8.17 and a 200 day simple moving average of $7.51. The firm has a market cap of $1.35 billion, a PE ratio of -6.45 and a beta of 1.28.

Ocular Therapeutix (NASDAQ:OCUL – Get Your Free Report ) last released its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.04). Ocular Therapeutix had a negative net margin of 226.46% and a negative return on equity of 52.75%. The business had revenue of $16.40 million during the quarter, compared to analyst estimates of $15.85 million. During the same period in the previous year, the firm posted EPS of ($0.27). The company’s revenue for the quarter was up 7.9% on a year-over-year basis. sell-side analysts anticipate that Ocular Therapeux will post -1.02 EPS for the current fiscal year.

Institutional inputs and outputs

Institutional investors and hedge funds have recently made changes to their positions in the stock. Great Point Partners LLC bought a new position in shares of Ocular Therapeutix in the 4th quarter valued at about $3,122,000. Artia Global Partners LP bought a new position in shares of Ocular Therapeutix in the 4th quarter worth about $1,962,000. Deltec Asset Management LLC boosted its holdings in shares of Ocular Therapeutix by 9.6% in the second quarter. Deltec Asset Management LLC now owns 2,590,265 shares of the biopharmaceutical company’s stock worth $17,717,000 after buying an additional 226,181 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in shares of Ocular Therapeutix by 1,142.3% in the first quarter. Price T Rowe Associates Inc. The MD now owns 662,672 shares of the biopharmaceutical company’s stock worth $6,031,000 after buying an additional 609,328 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Ocular Therapeutix by 41.4% in the first quarter. Vanguard Group Inc. now owns 7,235,131 shares of the biopharmaceutical company’s stock worth $65,840,000 after buying an additional 2,117,029 shares during the period. Institutional investors own 59.21% of the company’s shares.

Ocular Therapeutix Company Profile

(Get a free report

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development and commercialization of therapies for diseases and conditions of the eye using its hydrogel-based bioresorbable formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert for the treatment of post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.

Further reading

Receive Ocular Therapeutix news and reviews daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ocular Therapeutix and related companies with MarketBeat.com’s FREE daily email newsletter.